BioCentury
ARTICLE | Clinical News

Regeneron gains on Phase III data for RA compound

November 23, 2013 2:28 AM UTC

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) jumped $17.27 to $293.68 on Friday after the company and partner Sanofi (Euronext:SAN; NYSE:SNY) reported data from the Phase III portion of the Phase IIb/III SARIL-RA-MOBILITY trial evaluating sarilumab ( REGN88, SAR153191) to treat rheumatoid arthritis. In the trial, 150 and 200 mg subcutaneous sarilumab every other week plus methotrexate each met the three co-primary endpoints of improving ACR20 response rate at week 24 (58% and 66%, respectively, vs. 33%, p<0.001 for both), improving physical function from baseline to week 16 (p<0.001 for both) and of reducing the progression of structural damage from baseline to week 52 (p<0.001 for both) vs. placebo plus methotrexate. The double-blind, international trial enrolled about 1,200 patients with moderate to severe active RA who had an inadequate response to methotrexate. ...